These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 5160051)

  • 1. Psychomotor performances of patients undergoing L-dopa therapy.
    Davis LJ; Muenter MD
    Percept Mot Skills; 1971 Dec; 33(3):1303-8. PubMed ID: 5160051
    [No Abstract]   [Full Text] [Related]  

  • 2. Increase in fine motor control in Parkinson patients following levodopa.
    Marsh GG; Kravitz EA
    Percept Mot Skills; 1971 Aug; 33(1):211-5. PubMed ID: 5095787
    [No Abstract]   [Full Text] [Related]  

  • 3. Some quantitative behavioural changes in L-dopa therapy.
    Meier MJ; Baker AB; Martin WE
    Trans Am Neurol Assoc; 1970; 95():64-8. PubMed ID: 5514413
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical study of L-dopa in Parkinson's disease].
    Franken L; Noel G; Lhoas JP; Meyers C; Noel P; Ectors M
    Brux Med; 1972 Dec; 52(12):851-60. PubMed ID: 4575350
    [No Abstract]   [Full Text] [Related]  

  • 5. [Use of L-DOPA in the therapy of parkinsonism].
    D'Andrea F; De Divitiis E; Signorelli CD; Cerillo A; Tedeschi G
    Rass Int Clin Ter; 1971 Feb; 51(4):193-221. PubMed ID: 4930734
    [No Abstract]   [Full Text] [Related]  

  • 6. The influence of a previous thalamotomy on the L-dopa effects on mono-manual dexterity in parkinsonism.
    Knutsson E; Mårtensson A; Meyerson BA; Risberg AM
    Scand J Rehabil Med; 1973; 5(3):130-3. PubMed ID: 4754551
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of amantadine on some psychomotor performances in Parkinsonism. A double blind study.
    Laitinen LV; Vilkki J
    Ann Clin Res; 1971 Aug; 3(4):207-11. PubMed ID: 4937341
    [No Abstract]   [Full Text] [Related]  

  • 8. Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with L-dopa.
    Donnelly EF; Chase TN
    Dis Nerv Syst; 1973 Feb; 34(2):119-23. PubMed ID: 4706860
    [No Abstract]   [Full Text] [Related]  

  • 9. Psychiatric changes in patients treated with levodopa. I. The clinical experiment.
    Knopp W
    Neurology; 1970 Dec; 20(12):Suppl:23-30. PubMed ID: 4921585
    [No Abstract]   [Full Text] [Related]  

  • 10. Some quantitative behavioral changes in L-dopa therapy.
    Meier MJ; Baker AB; Martin WE
    Geriatrics; 1972 Jun; 27(6):89-97. PubMed ID: 5032486
    [No Abstract]   [Full Text] [Related]  

  • 11. [Psychological phenomenona during therapy with L-dopa. I].
    Pinto F; Venturini E
    Riv Neurobiol; 1970; 16(4):406-14. PubMed ID: 5527291
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Gauthier G; de Ajuriaguerra J; Simona B; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Neurol (Paris); 1970 Nov; 123(5):297-319. PubMed ID: 5513630
    [No Abstract]   [Full Text] [Related]  

  • 13. Experimental treatment of parkinsonism with L-Dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    Neurology; 1968 Mar; 18(3):276-7. PubMed ID: 4869717
    [No Abstract]   [Full Text] [Related]  

  • 14. [L-dopa and parkinsonism. A preliminary report].
    Pakkenberg H
    Ugeskr Laeger; 1969 May; 131(22):959-60. PubMed ID: 5793628
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitative effects of L-dopa on different types of movements and muscle tone in Parkinsonian patients.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1971; 3(3):121-30. PubMed ID: 5156174
    [No Abstract]   [Full Text] [Related]  

  • 16. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
    Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
    [No Abstract]   [Full Text] [Related]  

  • 17. Modification of Parkinsonism--chronic treatment with L-dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
    [No Abstract]   [Full Text] [Related]  

  • 18. [Silent period in patients with Parkinson's disease treated with L-Dopa].
    Palao Sánchez A
    Arch Neurobiol (Madr); 1973; 36(1):47-56. PubMed ID: 4706780
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long-term treatment of Parkinsonism with L-dopa].
    Presthus J; Holmsen R
    Tidsskr Nor Laegeforen; 1972 Nov; 92(33):2262-6. PubMed ID: 4630916
    [No Abstract]   [Full Text] [Related]  

  • 20. [Quantitative testing methods for objectification of the effect of prolonged L-dopa therapy in parkinsonism].
    Gerstenbrand F; Grünberger J; Schubert H
    Nervenarzt; 1973 Aug; 44(8):428-33. PubMed ID: 4733895
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.